Abstract
Introduction COVID-19 vaccination coverage in South Africa (RSA) remains low despite increased access to vaccines. On November 1, 2021, RSA introduced the Vooma Voucher program which provided a small guaranteed financial incentive, a Vooma Voucher redeemable at grocery stores, for COVID-19 vaccination among older adults, a population most vulnerable to serious illness, hospitalization, and death. However, the association of financial incentives with vaccination coverage remains unclear.
Methods We evaluated the association of the conditional economic incentive program with first-dose vaccination rates among adults (aged ≥60 years) through a quasi-experimental cohort study. The Vooma Voucher program was a nationwide vaccination incentive program implemented for adults aged ≥60 years from November 1, 2021 to February 28, 2022. We ran interrupted time series models to evaluate the Vooma Voucher program at national and provincial levels. We used data between October 1, 2021 and November 27, 2021 in models estimated at the daily level. Individuals who received their first vaccine dose received a text message to access a ZAR100 ($∼7) voucher that was redeemable at grocery stores.
Results The Vooma Voucher program was associated with a 7.15-12.01% increase in daily first-dose vaccinations in November 2021 compared to late October 2021. Overall, the incentive accounted for 6,476-10,874 additional first vaccine doses from November 1-27, 2021, or 8.31-13.95% of all doses administered to those aged ≥60 years during that period. This result is robust to the inclusion of controls for the number of active vaccine delivery sites and for the nationwide Vooma vaccination weekend initiative (November 12-14), both of which also increased vaccinations through expanded access to vaccines and demand creation activities.
Conclusions Financial incentives for COVID-19 vaccination led to a modest increase in first dose vaccinations among older adults in RSA. Financial incentives and expanded access to vaccines may result in higher vaccination coverage.
Trial registration number (SANCTR) DOH-27-012022-9116
What is already known about this topic?There is a lack of evidence on whether financial incentives for COVID-19 vaccinations are effective in low- and middle-income countries.
What does this study add?We found that a ZAR100 (∼US$7) incentive for adults aged ≥60 years increased additional first vaccine doses between November 1-27, 2021 to those aged ≥60 years during that period.
How this study might affect research, practice or policy?Small guaranteed financial incentives may be an effective strategy to increase vaccine demand among older adults in low- and middle-income countries.
Competing Interest Statement
Jacqui Miot is a member of the National Ministerial Advisory Committee on COVID-19 in South Africa. All other authors have declared no conflict of interest.
Funding Statement
This analysis was funded by the Bill and Melinda Gates Foundation (INV 036204).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Witwatersrand Human Research Ethics Committee (Medical) (211123) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title and the analysis section of the manuscript has been updated.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
